|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1996-5-28
|
|
pubmed:abstractText |
5-fluorouracil (5-FU) is a known radiosensitizer that enhances efficacy, in vivo and in vitro, when administered during radiotherapy. The following study was performed to evaluate the toxicity of continuous infusion 5-FU administered concomitant with brachytherapy in patients with locally advanced prostate cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
924-7
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8608485-Aged,
pubmed-meshheading:8608485-Antineoplastic Agents,
pubmed-meshheading:8608485-Brachytherapy,
pubmed-meshheading:8608485-Combined Modality Therapy,
pubmed-meshheading:8608485-Fluorouracil,
pubmed-meshheading:8608485-Gold Radioisotopes,
pubmed-meshheading:8608485-Humans,
pubmed-meshheading:8608485-Infusions, Intravenous,
pubmed-meshheading:8608485-Lymphatic Metastasis,
pubmed-meshheading:8608485-Male,
pubmed-meshheading:8608485-Middle Aged,
pubmed-meshheading:8608485-Prostatic Neoplasms,
pubmed-meshheading:8608485-Radiation-Sensitizing Agents,
pubmed-meshheading:8608485-Radiotherapy Dosage
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial.
|
|
pubmed:affiliation |
Department of Urology, The University of Iowa, Iowa City 52242-1089, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Clinical Trial, Phase I
|
